Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 211198, China.
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
Bioorg Med Chem Lett. 2021 Sep 1;47:128169. doi: 10.1016/j.bmcl.2021.128169. Epub 2021 Jun 6.
Two series of novel compounds with inhibition activity against PARP-1 were designed and synthesized. All target compounds were evaluated for their PARP-1 inhibition activity, and compounds with high PARP-1 inhibition activity were selected to assess for cellular assays in vitro. Among them, compound II-4 displayed impressive results in both PARP-1 enzyme inhibition with IC value of 0.51 nM and anti-proliferation activity against HCT116 and HCC1937 cell lines with IC values of 6.62 nM and 12.65 nM, respectively. Also, II-4 exhibited good metabolic stability in vitro with t of 173.25 min and CL of 0.04 mL/min/mg. Prediction of molecular properties and protein docking were applied to structure design. Our study provides potential lead compounds and design directions for the development of PARP-1 inhibitors.
设计并合成了两系列具有 PARP-1 抑制活性的新型化合物。所有目标化合物均进行了 PARP-1 抑制活性评估,并选择具有高 PARP-1 抑制活性的化合物进行体外细胞检测。其中,化合物 II-4 在 PARP-1 酶抑制方面表现出优异的效果,IC 值为 0.51 nM,对 HCT116 和 HCC1937 细胞系的增殖活性抑制作用的 IC 值分别为 6.62 nM 和 12.65 nM。此外,II-4 在体外具有良好的代谢稳定性,t 值为 173.25 分钟,CL 值为 0.04 mL/min/mg。还应用了分子性质预测和蛋白对接来进行结构设计。本研究为 PARP-1 抑制剂的开发提供了潜在的先导化合物和设计方向。